REAL TIME NET WORTH
as of 8/10/21
$3.3 B | 12.01%
Reflects change since 5 PM ET of prior trading day
- In 2005, Andreas Struengmann and twin brother Thomas sold their generic drugmaker Hexal (plus a stake in Eon Labs) to Novartis for some $7 billion.
- They cofounded Hexal in 1986. The company launched the highly successful cholesterol-lowering drug simvastatin, a substitute for Merck’s ZOCOR.
- The brothers invest in biotech, pharma, life sciences and healthcare companies through their Zug, Switzerland-based investment firm, Santo Holding.
- Their portfolio includes Germany’s BioNTech and Uruguay’s Mega Pharma, initially a joint venture with Argentine billionaire Alberto Roemmers.
- In 2008, they established a neuroscience research center in Frankfurt named after their father, Ernst Struengmann.
ON FORBES LISTS
SOURCE OF WEALTHpharmaceuticals, Self Made
EDUCATIONMedical Doctor, University at Buffalo
- Read more: https://www.forbes.com/profile/andreas-struengmann/?listuri=rtb&sh=646f62401109